CTN-0109: Randomized, Placebo-Controlled Trial of Injectable Naltrexone and Monthly Injectable Buprenorphine for Cocaine Use Disorder (CURB-2)

Madhukar Trivedi, MD
Lead Investigator
University of Texas, Southwestern Medical Center at Dallas
madhukar.trivedi@utsouthwestern.edu

Cocaine is one of the most commonly abused stimulants globally, and in the US,  there are signs of a resurgence of cocaine use. A variety of pharmacotherapies for cocaine use disorder (CUD) has been explored but so far, no study has findings robust enough to warrant FDA approval. Recent research suggests that a kappa opioid receptor antagonist can curb the negative emotional states associated with stimulant withdrawal that leads to increased craving and drug-seeking behaviors. This protocol builds up on results of the Cocaine Use Reduction with Buprenorphine (CURB) study. It aims to evaluate the safety and efficacy of combined monthly injections of XR-NTX and injectable BUP for CUD compared to placebo.

Related Studies

• CTN-0109-A-1: Innovative Development of Research Engagement Manual (I-DREM): Strategies to Enhance Recruitment and Retention of Black Individuals in CTN-0109 CURB-2

Related Research

• Publications in the Library about CTN-0109
• NIDA protocol page

Node Involvement

Lead Node(s):

Big South/West Node

All Participating Nodes:

Big South/West Node

Florida Node Alliance

Northstar Node